Developer docs
API playgroundTry for free, no card

Search company profiles

Biotech

Full company profile

uuid0006h8w

Namestring
Biotech
Legal namestring
Biotech Healthcare Holding GmbH
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Biotech Healthcare is a privately held global medical device company founded in 1999 by Mehul Asnani, organized as a group of legally independent companies under Biotech Healthcare Holding GmbH in Switzerland. The company designs, develops, manufactures, and sells specialty medical devices across three healthcare verticals: ophthalmology (its primary segment), orthopedics, and aesthetics. The ophthalmology portfolio is the most comprehensive and includes intraocular lenses (monofocal, toric, EDOF, and trifocal under the Optiflex brand), phakic lenses (Eyecryl) for refractive correction, ophthalmic viscosurgical devices (OVDs), surgical dyes, vitreoretinal temponades, intrastromal corneal ring segments (ISCR), and riboflavin for corneal cross-linking. The orthopedics vertical centers on OPTIVISC hyaluronic acid viscosupplement solutions for joint pain relief, and the aesthetics vertical offers hyaluronic acid dermal fillers.

The company's operating model is vertically integrated, with R&D and manufacturing facilities in Roscommon, Ireland (Biotech Europe Meditech Inc. Ltd.) and Ahmedabad, India (Biotech Vision Care Pvt. Ltd.), sales and marketing headquartered in Luzern, Switzerland, and distribution reaching more than 110 countries. Products are sold through B2B channels — direct to ophthalmologists, orthopedic surgeons, and aesthetic practitioners — typically via quote-based arrangements rather than disclosed pricing. The company invests in brand development through branded sub-portfolios (Optiflex, Eyecryl, Optivisc, Biotech Connect, ISCR), surgeon education via events such as the Global Phakic Users Meeting and major congresses like ESCRS, and digital infrastructure including a multilingual website in nine languages and the Biotech Connect mobile application for healthcare professionals. No institutional investors, venture capital backers, or parent company control signals were disclosed, suggesting founder or family ownership.

Short descriptiontext

Biotech Healthcare is a privately held Swiss-headquartered global medical device company founded in 1999 that designs, manufactures, and distributes intraocular lenses, phakic lenses, viscosupplements, and dermal fillers to ophthalmologists, orthopedic surgeons, and aesthetic practitioners across 110+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersLuzern, Switzerland
HQ citystring
Luzern
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic medical devices, intraocular lenses, viscosupplement solutions, dermal fillers, refractive surgical products
Industry2 codes
PRIMARYHLAHAJAH
Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAF
Cornea, External Disease & Refractive Surgery (LASIK/PRK)
NAICS code3 codes
  • Ophthalmic Goods Manufacturing339115
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Ophthalmic Goods3851
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Devices (Ophthalmology, Orthopedics, Aesthetics)
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Products
TypeHardware Sales
Description

Biotech Healthcare generates revenue through the sale of medical devices including intraocular lenses, phakic lenses, OVDs, viscosupplements, and dermal fillers to healthcare providers and surgical centers globally.

biotechhealthcare.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Eyecryl
Description

Phakic lens brand for vision correction

biotechhealthcare.com
+4 more records
Core offering1 text field

Biotech Healthcare manufactures and sells medical devices across three healthcare verticals: ophthalmology (intraocular lenses including monofocal, toric, EDOF, trifocal, and phakic lenses, plus OVDs, surgical dyes, temponades, riboflavin, and ISCR), orthopedics (OPTIVISC hyaluronic acid viscosupplement solutions for osteoarthritis), and aesthetics (hyaluronic acid dermal fillers). Products are sold B2B to ophthalmologists, surgeons, hospitals, and aesthetic practitioners in 110+ countries, with R&D and manufacturing in Ireland and India.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Biotech Healthcare operates as a global medical technology company with three distinct healthcare verticals: Ophthalmology, Orthopedics, and Aesthetics. The Ophthalmology division encompasses a comprehensive portfolio of intraocular lenses (IOLs) including premium EDOF and trifocal products like Optiflex XTENSE Comfort Plus and Optiflex Trio Plus, phakic lenses (Eyecryl Phakic) for refractive correction, surgical aids (OVDs, dyes, temponades), and corneal procedures (ISCR, riboflavin). The Orthopedics segment centers on viscosupplementation with OPTIVISC hyaluronic acid products for joint pain relief. The Aesthetics vertical offers hyaluronic acid-based dermal fillers. The company distributes across 110+ countries with R&D and manufacturing facilities in Ireland and India, and sales headquarters in Switzerland.

Product and service11 records
1Optiflex XTENSE Comfort Plus
CategoryOphthalmology - Intraocular Lenses
Description

Premium extended-depth-of-focus (EDOF) intraocular lens for cataract surgery that provides continuous vision correction across distance and intermediate ranges with enhanced depth of focus.

2Optiflex Trio Plus
CategoryOphthalmology - Intraocular Lenses
Description

Advanced intraocular lens combining trifocal and EDOF technologies to provide clear vision at near, intermediate, and distance ranges for cataract surgery patients.

3Eyecryl Phakic
CategoryOphthalmology - Refractive Lenses
Description

Implantable phakic intraocular lens for correction of moderate to severe myopia without removing the natural crystalline lens, designed for patients not suitable for laser refractive procedures.

4Intraocular Lenses (IOLs) Portfolio
CategoryOphthalmology - Intraocular Lenses
Description

Full portfolio of intraocular lenses including monofocal, toric, EDOF, and multifocal/trifocal options for cataract surgery and refractive correction.

5OPTIVISC Viscosupplement Solutions
CategoryOrthopedics - Viscosupplements
Description

Exogenous hyaluronic acid viscosupplement solutions for orthopedics that restore synovial fluid balance in osteoarthritis conditions, enhancing joint mobility and alleviating pain.

6Ophthalmic Viscosurgical Devices (OVDs)
CategoryOphthalmology - Surgical Aids
Description

Viscoelastic substances used during ophthalmic surgery to maintain space, protect tissues, and facilitate manipulation during cataract and other eye procedures.

7Surgical Dyes
CategoryOphthalmology - Surgical Aids
Description

Specialized staining solutions for ophthalmic surgery including trypan blue and brilliant blue G dyes for enhanced visualization during cataract procedures.

8Tamponades
CategoryOphthalmology - Vitreoretinal
Description

Vitreoretinal surgical products including silicone oil and perfluorocarbon liquids used as temporary internal tamponade agents during retinal detachment repair.

9Hyaluronic Acid Dermal Fillers
CategoryAesthetics - Dermal Fillers
Description

Premium aesthetic injectable fillers based on hyaluronic acid for natural, long-lasting facial enhancements and wrinkle reduction.

10ISCR (Intrastromal Corneal Ring Segments)
CategoryOphthalmology - Refractive
Description

Corneal ring implants for treatment of keratoconus and corneal ectasia, providing structural support and vision correction.

11Riboflavin Ophthalmic Solutions
CategoryOphthalmology - Corneal Procedures
Description

Ophthalmic riboflavin solutions used in corneal cross-linking procedures for treatment of progressive keratoconus.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-09
Description

Extended partnership through 2032 to develop genetic testing products using Oxford Nanopore's sequencing platforms. Collaboration builds on previous success with genetic screening kits and aims to accelerate diagnostic innovation and streamline workflows for genetic testing solutions globally.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in ophthalmic surgical devices including IOLs (PanOptix, Vivity), phakic IOLs, and OVDs. Directly competes with Biotech Healthcare across the entire ophthalmology portfolio and acquired STAAR Surgical to extend phakic lens leadership.

TypeBroad incumbent
Description

Major ophthalmic medical device company offering TECNIS IOL family (monofocal, multifocal, EDOF) and surgical products. Directly competes with Biotech Healthcare in cataract surgery IOLs and refractive solutions.

TypeBroad incumbent
Description

Diversified eye health company offering IOLs (enVista, LuxSmart), surgical instruments, and ophthalmic pharmaceuticals. Competes with Biotech Healthcare in IOLs and cataract surgical products.

4Carl Zeiss Meditec
TypeBroad incumbent
Description

Premium ophthalmic surgical microscope and IOL manufacturer (AT ELANA, CT LUCIA). Competes in the premium IOL segment and offers comprehensive cataract surgery solutions overlapping with Biotech Healthcare's portfolio.

TypeDirect peer
Description

Division of HOYA Corporation manufacturing IOLs (Vivinex, iSert) for cataract surgery. Directly comparable in IOL portfolio breadth and global distribution, targeting similar ophthalmic surgeon customers.

TypeDirect peer
Description

Specialist in Implantable Collamer Lens (ICL) phakic IOLs for refractive correction. Closest direct competitor to Biotech Healthcare's Eyecryl phakic lens portfolio in the surgical refractive correction segment.

TypeDirect peer
Description

Japanese manufacturer of ophthalmic surgical equipment, IOLs, and diagnostic devices. Comparable in offering surgical ophthalmic devices across cataract and refractive categories with global distribution.

TypeDirect peer
Description

Specialized IOL manufacturer focused on premium lens technologies including multifocal, toric, and EDOF IOLs. Directly comparable in scale and premium IOL portfolio positioning versus incumbent players.

9Santen Pharmaceutical
TypeDirect peer
Description

Specialty ophthalmology company with portfolio spanning cataract surgery, glaucoma, and dry eye. Comparable in ophthalmic vertical focus and global commercialization capabilities.

TypeEmerging player
Description

Emerging ophthalmic medical device company with IOL portfolio and growing global presence. Similar in being a non-incumbent challenger with multi-product ophthalmology portfolio targeting premium IOL segments.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biotech

Medical Devices (Ophthalmology, Orthopedics, Aesthetics)biotechhealthcare.com

Biotech Healthcare is a privately held Swiss-headquartered global medical device company founded in 1999 that designs, manufactures, and distributes intraocular lenses, phakic lenses, viscosupplements, and dermal fillers to ophthalmologists, orthopedic surgeons, and aesthetic practitioners across 110+ countries.

What Biotech does

Biotech Healthcare is a privately held global medical device company founded in 1999 by Mehul Asnani, organized as a group of legally independent companies under Biotech Healthcare Holding GmbH in Switzerland. The company designs, develops, manufactures, and sells specialty medical devices across three healthcare verticals: ophthalmology (its primary segment), orthopedics, and aesthetics. The ophthalmology portfolio is the most comprehensive and includes intraocular lenses (monofocal, toric, EDOF, and trifocal under the Optiflex brand), phakic lenses (Eyecryl) for refractive correction, ophthalmic viscosurgical devices (OVDs), surgical dyes, vitreoretinal temponades, intrastromal corneal ring segments (ISCR), and riboflavin for corneal cross-linking. The orthopedics vertical centers on OPTIVISC hyaluronic acid viscosupplement solutions for joint pain relief, and the aesthetics vertical offers hyaluronic acid dermal fillers.

The company's operating model is vertically integrated, with R&D and manufacturing facilities in Roscommon, Ireland (Biotech Europe Meditech Inc. Ltd.) and Ahmedabad, India (Biotech Vision Care Pvt. Ltd.), sales and marketing headquartered in Luzern, Switzerland, and distribution reaching more than 110 countries. Products are sold through B2B channels — direct to ophthalmologists, orthopedic surgeons, and aesthetic practitioners — typically via quote-based arrangements rather than disclosed pricing. The company invests in brand development through branded sub-portfolios (Optiflex, Eyecryl, Optivisc, Biotech Connect, ISCR), surgeon education via events such as the Global Phakic Users Meeting and major congresses like ESCRS, and digital infrastructure including a multilingual website in nine languages and the Biotech Connect mobile application for healthcare professionals. No institutional investors, venture capital backers, or parent company control signals were disclosed, suggesting founder or family ownership.

Biotech firmographics

Firmographics
Name
Biotech
Legal name
Biotech Healthcare Holding GmbH
Website
https://biotechhealthcare.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Biotech Healthcare is a privately held Swiss-headquartered global medical device company founded in 1999 that designs, manufactures, and distributes intraocular lenses, phakic lenses, viscosupplements, and dermal fillers to ophthalmologists, orthopedic surgeons, and aesthetic practitioners across 110+ countries.
Ownership category
akta.pro rank

Biotech industry classification

Industry
Product category
Medical Devices (Ophthalmology, Orthopedics, Aesthetics)
NAICS
Ophthalmic Goods Manufacturing (339115), Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
SIC
Ophthalmic Goods (3851), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAJAH
Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAF
Cornea, External Disease & Refractive Surgery (LASIK/PRK)

Keywords

  • Ophthalmic medical devices
  • Intraocular lenses
  • Viscosupplement solutions
  • Dermal fillers
  • Refractive surgical products

Where Biotech is headquartered

Location

Headquarters

HQ city
Luzern
HQ country
Switzerland
HQ region
Europe

Offices3 records

Markets served

Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Medical Device Products: Biotech Healthcare generates revenue through the sale of medical devices including intraocular lenses, phakic lenses, OVDs, viscosupplements, and dermal fillers to healthcare providers and surgical centers globally.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Biotech product offering

Product offering

Core offering

Biotech Healthcare manufactures and sells medical devices across three healthcare verticals: ophthalmology (intraocular lenses including monofocal, toric, EDOF, trifocal, and phakic lenses, plus OVDs, surgical dyes, temponades, riboflavin, and ISCR), orthopedics (OPTIVISC hyaluronic acid viscosupplement solutions for osteoarthritis), and aesthetics (hyaluronic acid dermal fillers). Products are sold B2B to ophthalmologists, surgeons, hospitals, and aesthetic practitioners in 110+ countries, with R&D and manufacturing in Ireland and India.

Product overview

Biotech Healthcare operates as a global medical technology company with three distinct healthcare verticals: Ophthalmology, Orthopedics, and Aesthetics. The Ophthalmology division encompasses a comprehensive portfolio of intraocular lenses (IOLs) including premium EDOF and trifocal products like Optiflex XTENSE Comfort Plus and Optiflex Trio Plus, phakic lenses (Eyecryl Phakic) for refractive correction, surgical aids (OVDs, dyes, temponades), and corneal procedures (ISCR, riboflavin). The Orthopedics segment centers on viscosupplementation with OPTIVISC hyaluronic acid products for joint pain relief. The Aesthetics vertical offers hyaluronic acid-based dermal fillers. The company distributes across 110+ countries with R&D and manufacturing facilities in Ireland and India, and sales headquarters in Switzerland.

Differentiator

Problem solved

Functional benefit

Brands

  • Eyecryl: Phakic lens brand for vision correction
  • Optiflex
  • Optivisc
  • Biotech Connect
  • ISCR

Products and services

  • Optiflex XTENSE Comfort Plus Premium extended-depth-of-focus (EDOF) intraocular lens for cataract surgery that provides continuous vision correction across distance and intermediate ranges with enhanced depth of focus.
  • Optiflex Trio Plus Advanced intraocular lens combining trifocal and EDOF technologies to provide clear vision at near, intermediate, and distance ranges for cataract surgery patients.
  • Eyecryl Phakic Implantable phakic intraocular lens for correction of moderate to severe myopia without removing the natural crystalline lens, designed for patients not suitable for laser refractive procedures.
  • Intraocular Lenses (IOLs) Portfolio Full portfolio of intraocular lenses including monofocal, toric, EDOF, and multifocal/trifocal options for cataract surgery and refractive correction.
  • OPTIVISC Viscosupplement Solutions Exogenous hyaluronic acid viscosupplement solutions for orthopedics that restore synovial fluid balance in osteoarthritis conditions, enhancing joint mobility and alleviating pain.
  • Ophthalmic Viscosurgical Devices (OVDs) Viscoelastic substances used during ophthalmic surgery to maintain space, protect tissues, and facilitate manipulation during cataract and other eye procedures.
  • Surgical Dyes Specialized staining solutions for ophthalmic surgery including trypan blue and brilliant blue G dyes for enhanced visualization during cataract procedures.
  • Tamponades Vitreoretinal surgical products including silicone oil and perfluorocarbon liquids used as temporary internal tamponade agents during retinal detachment repair.
  • Hyaluronic Acid Dermal Fillers Premium aesthetic injectable fillers based on hyaluronic acid for natural, long-lasting facial enhancements and wrinkle reduction.
  • ISCR (Intrastromal Corneal Ring Segments) Corneal ring implants for treatment of keratoconus and corneal ectasia, providing structural support and vision correction.
  • Riboflavin Ophthalmic Solutions Ophthalmic riboflavin solutions used in corneal cross-linking procedures for treatment of progressive keratoconus.

Companies that use Biotech

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Biotech technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Biotech partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Oxford Nanopore TechnologiescoreTechnology or Integration · 9 October 2025Extended partnership through 2032 to develop genetic testing products using Oxford Nanopore's sequencing platforms. Collaboration builds on previous success with genetic screening kits and aims to accelerate diagnostic innovation and streamline workflows for genetic testing solutions globally.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Biotech competitors and assessment

Company assessment

Broad incumbents

  • Alcon: Global leader in ophthalmic surgical devices including IOLs (PanOptix, Vivity), phakic IOLs, and OVDs. Directly competes with Biotech Healthcare across the entire ophthalmology portfolio and acquired STAAR Surgical to extend phakic lens leadership.
  • Johnson & Johnson Vision: Major ophthalmic medical device company offering TECNIS IOL family (monofocal, multifocal, EDOF) and surgical products. Directly competes with Biotech Healthcare in cataract surgery IOLs and refractive solutions.
  • Bausch + Lomb: Diversified eye health company offering IOLs (enVista, LuxSmart), surgical instruments, and ophthalmic pharmaceuticals. Competes with Biotech Healthcare in IOLs and cataract surgical products.
  • Carl Zeiss Meditec: Premium ophthalmic surgical microscope and IOL manufacturer (AT ELANA, CT LUCIA). Competes in the premium IOL segment and offers comprehensive cataract surgery solutions overlapping with Biotech Healthcare's portfolio.

Direct peers

  • HOYA Surgical Optics: Division of HOYA Corporation manufacturing IOLs (Vivinex, iSert) for cataract surgery. Directly comparable in IOL portfolio breadth and global distribution, targeting similar ophthalmic surgeon customers.
  • STAAR Surgical (now Alcon): Specialist in Implantable Collamer Lens (ICL) phakic IOLs for refractive correction. Closest direct competitor to Biotech Healthcare's Eyecryl phakic lens portfolio in the surgical refractive correction segment.
  • Nidek: Japanese manufacturer of ophthalmic surgical equipment, IOLs, and diagnostic devices. Comparable in offering surgical ophthalmic devices across cataract and refractive categories with global distribution.
  • Lenstec: Specialized IOL manufacturer focused on premium lens technologies including multifocal, toric, and EDOF IOLs. Directly comparable in scale and premium IOL portfolio positioning versus incumbent players.
  • Santen Pharmaceutical: Specialty ophthalmology company with portfolio spanning cataract surgery, glaucoma, and dry eye. Comparable in ophthalmic vertical focus and global commercialization capabilities.

Emerging players

  • VSY Biotechnology: Emerging ophthalmic medical device company with IOL portfolio and growing global presence. Similar in being a non-incumbent challenger with multi-product ophthalmology portfolio targeting premium IOL segments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks4 records

Key highlights7 records

Customer concentration

Biotech compliance and trust

Trust signal

Compliance1 record

Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biotech leadership team

Management profile

Number of profiles

Profiles1 record

Biotech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biotech

What does Biotech do?

Biotech Healthcare manufactures and sells medical devices across three healthcare verticals: ophthalmology (intraocular lenses including monofocal, toric, EDOF, trifocal, and phakic lenses, plus OVDs, surgical dyes, temponades, riboflavin, and ISCR), orthopedics (OPTIVISC hyaluronic acid viscosupplement solutions for osteoarthritis), and aesthetics (hyaluronic acid dermal fillers). Products are sold B2B to ophthalmologists, surgeons, hospitals, and aesthetic practitioners in 110+ countries, with R&D and manufacturing in Ireland and India.

Is Biotech a public or private company?

Biotech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Biotech founded?

Biotech was founded in 1999. It employs 1,001 to 5,000 people.

Where is Biotech based?

Biotech is headquartered in Luzern, Switzerland, in the Europe region.

How does Biotech make money?

One revenue line is on record: medical Device Products.

Who are Biotech's main competitors?

Broad incumbents on record are Alcon, Johnson & Johnson Vision, Bausch + Lomb and Carl Zeiss Meditec. Direct peers are HOYA Surgical Optics, STAAR Surgical (now Alcon), Nidek, Lenstec and Santen Pharmaceutical. VSY Biotechnology is listed as an emerging player.

Does Biotech have an API?

No public API is recorded for Biotech.

What industry is Biotech in?

Biotech's product category is Medical Devices (Ophthalmology, Orthopedics, Aesthetics). Its primary akta.pro industry code is HLAHAJAH, Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics), with a secondary code of HLAKAKAF, Cornea, External Disease & Refractive Surgery (LASIK/PRK). Its NAICS code is 339115 and its SIC code is 3851.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Ophthalmology TimesBiotech Healthcare secures EU MDR certification for ophthalmic and medical devicesBiotech Healthcare announced it has achieved certification under the European Union's Medical Device Regulation (MDR) for a range of ophthalmic and medical devices manufactured in India. The certification covers products including intraocular lenses, surgical devices, sterile solutions for osteoarthritis, and hyaluronic acid gel for dermal use. The company stated that MDR certification enables continued access to the European market, supports reinforced clinical confidence through validated safety standards, and provides greater distributor confidence through portfolio stability.Investing.comHealthcare: Pockets of Alpha | Investing.comThe article discusses the performance of the Healthcare sector within the S&P 500, highlighting its 3.8% decline year-to-date, which is the worst among all sectors. Despite weak overall performance, selected industries like Pharmaceuticals and Biotech show some improving outlooks, particularly due to M&A activity and earnings recovery prospects. The article suggests a market-weight position in Healthcare, focusing on areas with improving earnings and margins.openPR.comPlacental Stem Cell Therapy Market to Reach US$ 1,770 Million by 2032 at 18.5% CAGRAnalystView Market Insights published a market research report projecting the Placental Stem Cell Therapy Market will grow from US$ 455 million in 2024 to US$ 1,770 million by 2032, representing a CAGR of 18.5%. The report identifies biotechnology advancements, improved stem cell isolation techniques, and increasing clinical research as primary growth drivers, while citing stringent regulatory requirements and high therapy costs as key challenges limiting patient accessibility.Investing.comBio-Techne at TD Cowen Conference: Strategic Growth and Challenges By Investing.comBio-Techne presented at the TD Cowen Healthcare Conference discussing its strategic growth plans and challenges, including a focus on achieving mid-single-digit organic growth by fiscal 2026. The company highlighted strong pharma performance, biotech funding surges, and upcoming acquisitions like Wilson Wolf to bolster its reagent and cell therapy businesses.HrtodayPankaj Phatak Appointed as Vice President – HR (Global Human Resources) at Biotech Healthcare GroupBiotech Healthcare Group announced the appointment of Pankaj Phatak as Vice President – HR (Global Human Resources), a role in which he will lead the company's global people strategy, talent architecture, and culture transformation agenda across its operations spanning more than 100 countries. Phatak joins from Dr. Reddy's Laboratories where he spent over two decades, most recently serving as Director & Group HR Head – Central Functions for Global Manufacturing Operations. The appointment strengthens Biotech Healthcare's leadership team as the life sciences company continues to expand its international presence across manufacturing, R&D, and commercial operations.Nova One AdvisorCRISPR-based Gene Editing Market Size to Reach USD 28.77 Billion by 2035The global CRISPR-based gene editing market is projected to grow from USD 7.25 billion in 2025 to USD 28.77 billion by 2035, at a compound annual growth rate of 14.78%, driven by rising genetic disorder prevalence, continuous CRISPR technology advancements, and increasing investments in personalized and regenerative medicine. North America currently dominates the market with the largest share, while the Asia-Pacific region is expected to witness the fastest growth over the forecast period, supported by expanding biotechnology sectors in China and India. AI integration into CRISPR workflows is accelerating guide RNA design, off-target prediction, and therapeutic target discovery, further propelling market expansion across biomedical and agricultural applications.Precedence ResearchIntraocular Lens Market Size to Hit USD 8.09 Billion by 2035The global intraocular lens market is projected to grow from USD 5.10 billion in 2025 to USD 8.09 billion by 2035, expanding at a CAGR of 4.72%, driven by rising cataract surgery incidence, an aging population, and increasing demand for premium lens technologies. North America held the largest market share at 37% in 2025, while Europe is expected to be the fastest-growing region. Key market developments include Johnson & Johnson's June 2025 rollout of the TECNIS Odyssey IOL in Europe, the Middle East, and Canada; Biotech Healthcare's October 2025 European launch of the Optiflex XTENSE Comfort Plus EDOF IOL; and ZEISS Medical Technology's introduction of new ophthalmic microscopes and IOLs at the APAO AIOC 2025 conference.Deloitte United StatesLife sciences M&A, divestments and restructuringThe article analyzes the significant rebound in life sciences M&A activity, driven by investor activism and the need to offset patent expirations, with deal values reaching US$163bn in 2023. It highlights the increasing role of GenAI in optimizing due diligence, target screening, and valuation precision for pharmaceutical and biotech companies. The report projects continued consolidation and strategic partnerships through 2030 as firms restructure portfolios to address the anticipated 'patent cliff' losing over US$236bn in revenue.BioSpaceThe First Annual BioTechX USA: Blending Science and TechnologyThe first annual BioTechX USA conference was held in Santa Clara in September, bringing together life sciences leaders across four tracks. It featured speakers from academia, regulators, venture capital, and pharma, with panelists discussing AI in drug development and data ethics. Organizers plan a 2024 event in the northeast with a gene therapies track.BloombergEx-Goldman Banker Uses Big Data to Beat Biotech’s Long OddsSimone Song, former Goldman Sachs health banking head for China, founded a venture fund in 2015 to bet on biotech winners using bespoke analysis. She emphasizes quantifying risk as the industry struggles with a downturn.